Editas Medicine, Inc.

Editas Medicine is a biotechnology company developing gene editing treatments using CRISPR, a technology that allows doctors to modify a patient's DNA to treat disease. The company's main focus is a therapy called EDIT-401, designed as a one-time treatment to lower cholesterol levels in people with high cholesterol. Editas is also working on treatments for blood disorders like sickle cell disease and beta thalassemia, as well as cancer and autoimmune diseases, in collaboration with another company called Juno Therapeutics. The company is based in Cambridge, Massachusetts and is still in the re...